ZYME$23.29
Chart
Performance
Key Stats
AI ZYME Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyZymeworks shows strong fundamental and thematic potential, particularly in its innovative biotherapeutics pipeline. However, recent financial performance indicates a need for careful monitoring, and technical indicators suggest a mixed short-term outlook.
Thematic
Zymeworks is positioned in the high-growth biotechnology sector, focusing on cancer and autoimmune diseases, with promising therapeutic platforms and a lead drug candidate in late-stage trials.
Fundamental
While revenue has shown some growth, the company is experiencing significant net losses. The balance sheet appears healthy with ample cash, but the lack of profitability and consistent negative free cash flow requires attention.
Technical
The stock has experienced significant upward momentum in the short term, trading above key moving averages. However, some oscillators indicate it might be approaching overbought conditions.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 95 |
| Therapeutic Focus | 90 |
| Drug Development Technology | 80 |
| Strategic Partnerships | 75 |
| Market Adoption Potential | 85 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 30 |
| Balance Sheet Health | 70 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 90 |
| Momentum | 60 |
| Volume Confirmation | 65 |
| Support & Resistance | 70 |
| Short-term Oscillators | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (9)
Positive Short-Term Performance
The stock has shown a significant increase of 16.67% in the last month, indicating positive short-term momentum.
Strong Year-to-Date Performance
The stock has experienced a 48.88% increase over the last year, demonstrating strong long-term performance.
Bearish Points (10)
Negative Earnings Per Share (EPS)
The company has consistently reported negative EPS in recent quarters, with EPS estimates for 2025 also being negative, indicating ongoing unprofitability.
Significant Negative Surprise in EPS
Q1 2025 EPS estimate was -0.1, but reported EPS was -0.31, a surprise of -213.13%, indicating a substantial miss on earnings expectations.
Calendar
August 2025
8
Next Earnings Date
H: $-0.32
A: $-0.46
L: $-0.58
H: 27.00M
A: 17.18M
L: 10.00M
Profile
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Seasonals
Price Target
21.56 USD
The 39 analysts offering 1 year price forecasts for ZYME have a max estimate of 30.00 and a min estimate of 12.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Acquired Seagen, a leading company in Antibody-Drug Conjugates (ADCs), making Pfizer a major competitor in the ADC space relevant to Zymeworks' core technology.
Weight: 95
A leader in developing and commercializing next-generation Antibody-Drug Conjugates (ADCs), including Enhertu, making them a primary competitor in Zymeworks' therapeutic area.
Weight: 92
A pure-play Antibody-Drug Conjugate (ADC) company with its own approved ADC (Elahere) and a robust pipeline, directly competing with Zymeworks in the ADC oncology space.
Weight: 90
Significant oncology presence, including a strong focus on Antibody-Drug Conjugates (ADCs) through partnerships (e.g., Enhertu with Daiichi Sankyo) and internal development.